Potential natural mTOR inhibitors screened by in silico approach and suppress hepatic stellate cells activation

References

• Balani, S. K., Miwa, G. T., Gan, L. S., Wu, J. T., & Lee, F. W. (2005). Strategy of utilizing in vitro and in vivo ADME tools for lead optimization and drug candidate selection. Current Topics in Medicinal Chemistry, 5, 1033–1038.10.2174/156802605774297038
   PubMed Web of Science ®Google Scholar
• Beevers, C. S., Li, F., Liu, L., & Huang, S. (2006). Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. International Journal of Cancer, 119, 757–764.10.1002/(ISSN)1097-0215
   PubMed Web of Science ®Google Scholar
• Bjornsti, M. A., & Houghton, P. J. (2004). The tor pathway: A target for cancer therapy. Nature Reviews Cancer, 4, 335–348.10.1038/nrc1362
   PubMed Web of Science ®Google Scholar
• Blaner, W. S., O’Byrne, S. M., Wongsiriroj, N., Kluwe, J., D’Ambrosio, D. M., Jiang, H., … Libien, J. (2009). Hepatic stellate cell lipid droplets: A specialized lipid droplet for retinoid storage. Biochimica et Biophysica Acta (BBA) – Molecular and Cell Biology of Lipids, 1791, 467–473.10.1016/j.bbalip.2008.11.001
   PubMed Web of Science ®Google Scholar
• Capra, J. A., Laskowski, R. A., Thornton, J. M., Singh, M., & Funkhouser, T. A. (2009). Predicting protein ligand binding sites by combining evolutionary sequence conservation and 3D structure. PLoS Computational Biology, 5(12), e1000585. doi:10.1371/journal.pcbi.1000585
   PubMed Web of Science ®Google Scholar
• Chang, K. T., Tsai, M. J., Cheng, Y. T., Chen, J. J., Hsia, R. H., Lo, Y. S., … Weng, C. F. (2009). Comparative atomic force and scanning electron microscopy: An investigation of structural differentiation of hepatic stellate cells. Journal of Structural Biology, 167, 200–208.10.1016/j.jsb.2009.06.005
   PubMed Web of Science ®Google Scholar
• Chen, K. C., Lee, W. Y., Chen, H. Y., & Chen, C. Y. (2014). In silico investigation of potential mTOR inhibitors from traditional Chinese medicine for treatment of Leigh syndrome. Biomedical Research International, 2014, 139492. doi:10.1155/2014/139492
   PubMed Web of Science ®Google Scholar
• Cheng, A. L., Hsu, C. H., Lin, J. K., Hsu, M. M., Ho, Y. F., Shen, T. S., … Hsieh, C. Y. (2001). Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Research, 21, 2895–2900.
   PubMed Web of Science ®Google Scholar
• Chiang, P. C., Lin, S. C., Pan, S. L., Kuo, C. H., Tsai, I. L., Kuo, M. T., … Guh, J. H. (2010). Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: A crucial role of AMPK and mTOR pathways. Biochemical Pharmacology, 79, 162–171.10.1016/j.bcp.2009.08.022
   PubMed Web of Science ®Google Scholar
• Choi, J., Chen, J., Schreiber, S. L., & Clardy, J. (1996). Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science, 273, 239–242.10.1126/science.273.5272.239
   PubMed Web of Science ®Google Scholar
• Choi, I., Park, Y., Choi, H., & Lee, E. H. (2006). Anti-adipogenic activity of rutin in 3T3-L1 cells and mice fed with high-fat diet. BioFactors, 26, 273–281.10.1002/biof.v26:4
   PubMed Web of Science ®Google Scholar
• Choo, A. Y., & Blenis, J. (2009). Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy. Cell Cycle, 8, 567–572.10.4161/cc.8.4.7659
   PubMed Web of Science ®Google Scholar
• Dos Santos, S., Delattre, A. I., De Longueville, F., Bult, H., & Raes, M. (2007).  Gene expression profiling of LPS-stimulated murine macrophages and role of the NF-kappaB and PI3K/mTOR signaling pathways. Annals of the New York Academy of Sciences, 1096, 70–77.10.1196/annals.1397.071
   PubMed Web of Science ®Google Scholar
• Elsharkawy, A. M., Oakley, F., & Mann, D. A. (2005). The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis, 10, 927–939.10.1007/s10495-005-1055-4
   PubMed Web of Science ®Google Scholar
• Erlund, I., Kosonen, T., Alfthan, G., Mäenpää, J., Perttunen, K., Kenraali, J., … Aro, A. (2000). Pharmacokinetics of quercetin from quercetin aglycone and rutin in healthy volunteers. European Journal of Clinical Pharmacology, 56(8), 545–553.10.1007/s002280000197
   PubMed Web of Science ®Google Scholar
• Ewing, T. J., Makino, S., Skillman, A. G., & Kuntz, I. D. (2001). DOCK 4.0: Search strategies for automated molecular docking of flexible molecule databases. Journal of Computer-Aided Molecular Design, 15, 411–428.10.1023/A:1011115820450
   PubMed Web of Science ®Google Scholar
• Gäbele, E., Reif, S., Tsukada, S., Bataller, R., Yata, Y., Morris, T., … Rippe, R. A. (2005).  The role of p70S6 K in hepatic stellate cell collagen gene expression and cell proliferation. Journal of Biological Chemistry, 280, 13374–13382.10.1074/jbc.M409444200
   PubMed Web of Science ®Google Scholar
• Gao, Y. D., & Huang, J. F. (2011). An extension strategy of Discovery Studio 2.0 for non-bonded interaction energy automatic calculation at the residue level. Dongwuxue Yanjiu, 32, 262–266.
   PubMedGoogle Scholar
• Girija, C. R., Karunakar, P., Poojari, C. S., Begum, N. S., & Syed, A. A. (2010). Molecular docking studies of molecular docking studies of curcumin derivatives with multiple protein targets for procarcinogen activating enzyme inhibition. Journal of Proteomics & Bioinformatics, 3(06), 200–203.10.4172/jpb
   Google Scholar
• Grifo, F., Newman, D., Fairfield, A., Bhattacharya, B. & Grupenhoff, J. (1997). The origins of prescription drugs. In F. Grifo & J. Rosenthal (Eds.), Biodiversity and human health (pp. 131–163). Washington, DC: Island Press.
   Google Scholar
• Huang, S., Bjornsti, M. A., & Houghton, P. J. (2003). Rapamycins: Mechanism of action and cellular resistance. Cancer Biology & Therapy, 2, 222–232.10.4161/cbt.2.3.360
   PubMed Web of Science ®Google Scholar
• Ji, H. F., Li, X. J., & Zhang, H. Y. (2009). Natural products and drug discovery. Can thousands of years of ancient medical knowledge lead us to new and powerful drug combinations in the fight against cancer and dementia? EMBO reports, 10, 194–200.10.1038/embor.2009.12
   PubMed Web of Science ®Google Scholar
• Khanfar, M. A., AbuKhader, M. M., Alqtaishat, S., & Taha, M. O. (2013). Pharmacophore modeling, homology modeling, and in silico screening reveal mammalian target of rapamycin inhibitory activities for sotalol, glyburide, metipranolol, sulfamethizole, glipizide, and pioglitazone. Journal of Molecular Graphics and Modelling, 42, 39–49.10.1016/j.jmgm.2013.02.009
   PubMed Web of Science ®Google Scholar
• Khanfar, M. A., Bardaweel, S. K., Akl, M. R., & El Sayed, K. A. (2015). Olive oil-derived Oleocanthal as potent inhibitor of mammalian target of rapamycin: Biological evaluation and molecular modeling studies. Phytotherapy Research, 29(11), 1776–1782. doi:10.1002/ptr.5434
   PubMed Web of Science ®Google Scholar
• Kist, R., & Caceres, R. A. (2016). New potential inhibitors of mTOR: A computational investigation integrating molecular docking, virtual screening and molecular dynamics simulation. Journal of Biomolecular Structure and Dynamics, 9, 1–14. doi:10.1080/07391102.2016.1262279
   Web of Science ®Google Scholar
• Kitchen, D. B., Decornez, H., Furr, J. R., & Bajorath, J. (2004). Docking and scoring in virtual screening for drug discovery: Methods and applications. Nature Reviews Drug Discovery, 3(11), 935–949.10.1038/nrd1549
   PubMed Web of Science ®Google Scholar
• Krief, S., Martin, M. T., Grellier, P., Kasenene, J., & Sevenet, T. (2004). Novel antimalarial compounds isolated in a survey of self-medicative behavior of wild chimpanzees in Uganda. Antimicrobial Agents and Chemotherapy, 48, 3196–3199.10.1128/AAC.48.8.3196-3199.2004
   PubMed Web of Science ®Google Scholar
• Kumar, V. B., Yuan, T. C., Liou, J. W., Yang, C. J., Sung, P. J., & Weng, C. F. (2011). Antroquinonol inhibits NSCLC proliferation by altering PI3 K/mTOR proteins and miRNA expression profiles. Mutation Research/Fundamental and Molecular Mechanisms of Mutagenesis, 707, 42–52.10.1016/j.mrfmmm.2010.12.009
   PubMed Web of Science ®Google Scholar
• Lakhlili, W., Yasri, A. & Ibrahimi, A. (2016). Structure-activity relationships study of mTOR kinase inhibition using QSAR and structure-based drug design approaches. OncoTargets and Therapy, 9: 7345–7353. eCollection 2016.10.2147/OTT
   PubMed Web of Science ®Google Scholar
• Laplante, M., & Sabatini, D. M. (2012). mTor signaling in growth control and disease. Cell, 149, 274–293.10.1016/j.cell.2012.03.017
   PubMed Web of Science ®Google Scholar
• Lee, K. W., Thiyagarajan, V., Sie, H. W., Cheng, M. F., Tsai, M. J., Chia, Y. C., & Weng, C. F. (2014). Synergistic effect of natural compounds on the fatty acid-induced autophagy of activated hepatic stellate cells. The Journal of Nutritional Biochemistry, 25, 903–913.10.1016/j.jnutbio.2014.04.001
   PubMed Web of Science ®Google Scholar
• Leone, M., Crowell, K. J., Chen, J., Jung, D., Chiang, G. G., Sareth, S., … Pellecchia, M. (2006). The FRB domain of mTOR: NMR solution structure and inhibitor design. Biochemistry, 45, 10294–10302.10.1021/bi060976+
   PubMed Web of Science ®Google Scholar
• Leong, M. K., Syu, R. G., Ding, Y. L., & Weng, C. F. (2017). Prediction of N-Methyl-D-Aspartate receptor GluN1-ligand binding affinity by a novel SVM-Pose/SVM-score combinatorial ensemble docking scheme. Scientific Reports, 7, 40053. doi:10.1038/srep40053
   PubMed Web of Science ®Google Scholar
• Liang, J., Choi, J., & Clardy, J. (1999). Refined structure of the FKBP12-rapamycin-FRB ternary complex at 2.2 Å resolution. Acta Crystallographica Section D Biological Crystallography, 55(4), 736–744.10.1107/S0907444998014747
   PubMedGoogle Scholar
• Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. F. (2001). Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews, 46(1–3), 3–26.10.1016/S0169-409X(00)00129-0
   PubMed Web of Science ®Google Scholar
• Liu, Q., Chen, J., Wang, X., Yu, L., Hu, L. H., & Shen, X. (2010a). Withagulatin A inhibits hepatic stellate cell viability and procollagen I production through Akt and Smad signaling pathways. Acta Pharmacologica Sinica, 31, 944–952.10.1038/aps.2010.72
   PubMed Web of Science ®Google Scholar
• Liu, Q., Wang, X., Zhang, Y., Li, C. J., Hu, L. H., & Shen, X. (2010b). Leukamenin F suppresses liver fibrogenesis by inhibiting both hepatic stellate cell proliferation and extracellular matrix production. Acta Pharmacologica Sinica, 31, 839–848.10.1038/aps.2010.64
   PubMed Web of Science ®Google Scholar
• Luo, Y., & Wang, L. (2017). Discovery and development of ATP-competitive mTOR inhibitors using computational approaches. Current Pharmaceutical Design. doi:10.2174/1381612823666170710150604
   Web of Science ®Google Scholar
• Lv, X., Ma, X., & Hu, Y. (2013). Furthering the design and the discovery of small molecule ATP-competitive mTOR inhibitors as an effective cancer treatment. Expert Opinion on Drug Discovery, 8, 991–1012. doi:10.1517/17460441.2013.800479
   PubMed Web of Science ®Google Scholar
• Meanwell, N. A. (2011). Improving drug candidates by design: A focus on physicochemical properties as a means of improving compound disposition and safety. Chemical Research in Toxicology, 24(9), 1420–1456. doi:10.1021/tx200211v
   PubMed Web of Science ®Google Scholar
• Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., & Olson, A. J. (1998). Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. Journal of Computational Chemistry, 19, 1639–1662.10.1002/(ISSN)1096-987X
   Web of Science ®Google Scholar
• Neef, M., Ledermann, M., Saegesser, H., Schneider, V., & Reichen, J. (2006). Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. Journal of Hepatology, 45, 786–796.10.1016/j.jhep.2006.07.030
   PubMed Web of Science ®Google Scholar
• Pan, S. Y., Zhou, S. F., Gao, S. H., Yu, Z. L., Zhang, S. F., Tang, M. K., … Ko, K. M. (2013). New perspectives on how to discover drugs from herbal medicines: CAM’s outstanding contribution to modern therapeutics. Evidence-Based Complementary and Alternative Medicine (eCAM), 2013, 627375.
   PubMed Web of Science ®Google Scholar
• Prakobwong, S., Khoontawad, J., Yongvanit, P., Pairojkul, C., Hiraku, Y., Sithithaworn, P., … Pinlaor, S. (2011). Curcumin decreases cholangiocarcinogenesis in hamsters by suppressing inflammation-mediated molecular events related to multistep carcinogenesis. International Journal of Cancer, 129, 88–100.10.1002/ijc.v129.1
   PubMed Web of Science ®Google Scholar
• Rosborough, B. R., Raïch-Regué, D., Liu, Q., Venkataramanan, R., Turnquist, H. R., & Thomson, A. W. (2014). Adenosine triphosphate-competitive mTOR inhibitors: A new class of immunosuppressive agents that inhibit allograft rejection. American Journal of Transplantation, 14, 2173–2180. doi:10.1111/ajt.12799
   PubMed Web of Science ®Google Scholar
• Sarbassov, D. D., Ali, S. M., & Sabatini, D. M. (2005). Growing roles for the mTOR pathway. Current Opinion in Cell Biology, 17, 596–603.10.1016/j.ceb.2005.09.009
   PubMed Web of Science ®Google Scholar
• Stanciu, A., Cotutiu, C., & Amalinei, C. (2002). New data about ITO cells. Revista Medico-Chiruricala A Societatii de Medici si Naturalisti Din Iasi (Iasi), 107, 235–239.
   Google Scholar
• Sunde, M., & Blake, C. (1997). The structure of amyloid fibrils by electron microscopy and x-ray diffraction. Protein Chemistry, 50, 123–159.
   Google Scholar
• Tan, S., Tam, M. M., & Nixon, R. L. (2011). Allergic contact dermatitis to Myroxylon pereirae (Balsam of Peru) in papaw ointment causing cheilitis. Australasian Journal of Dermatology, 52(3), 222–223.10.1111/j.1440-0960.2011.00772.x
   PubMed Web of Science ®Google Scholar
• Thiyagarajan, V., Lin, S. H., Chang, Y. C., & Weng, C. F. (2016). Identification of novel FAK and S6K1 dual inhibitors from natural compounds via ADMET screening and molecular docking. Biomedicine & Pharmacotherapy, 80, 52–62.10.1016/j.biopha.2016.02.020
   PubMed Web of Science ®Google Scholar
• Thiyagarajan, V., Lin, S. H., Chia, Y. C., & Weng, C. F. (2013). A novel inhibitor, 16-hydroxycleroda-3,13-dien-16,15-olide, blocks the autophosphorylation site of focal adhesion kinase (Y397) by molecular docking. Biochimica et Biophysica Acta (BBA) – General Subjects, 1830, 4091–4101.10.1016/j.bbagen.2013.04.027
   PubMed Web of Science ®Google Scholar
• Thiyagarajan, V., Tsai, M. J., & Weng, C. F. (2015). Antroquinonol targets FAK-signaling pathway suppressed cell migration, invasion, and tumor growth of C6 glioma. PLoS One, 10, e0141285.10.1371/journal.pone.0141285
   PubMed Web of Science ®Google Scholar
• Tomiya, T., Nishikawa, T., Inoue, Y., Ohtomo, N., Ikeda, H., Tejima, K., … Fujiwara, K. (2007). Leucine stimulates HGF production by hepatic stellate cells through mTOR pathway. Biochemical and Biophysical Research Communications, 358, 176–180.10.1016/j.bbrc.2007.04.093
   PubMed Web of Science ®Google Scholar
• Tran, L., Choi, S. B., Al-Najjar, B. O., Yusuf, M., Wahab, H. A., & Le, L. (2011). Discovery of potential M2 channel inhibitors based on the amantadine scaffold via virtual screening and pharmacophore modeling. Molecules, 16, 10227–10255.10.3390/molecules161210227
   PubMed Web of Science ®Google Scholar
• Tsang, C. K., Qi, H., Liu, L. F., & Zheng, X. F. S. (2007). Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discovery Today, 12 (3–4): 113–124.b
   Web of Science ®Google Scholar
• Veverka, V., Crabbe, T., Bird, I., Lennie, G., Muskett, F. W., Taylor, R. J., & Carr, M. D. (2008). Structural characterization of the interaction of mTOR with phosphatidic acid and a novel class of inhibitor: Compelling evidence for a central role of the FRB domain in small molecule-mediated regulation of mTOR. Oncogene, 27, 585–595.10.1038/sj.onc.1210693
   PubMed Web of Science ®Google Scholar
• Wang, R., Lu, Y., & Wang, S. (2003). Comparative evaluation of 11 scoring functions for molecular docking. Journal of Medicinal Chemistry, 46, 2287–2303.10.1021/jm0203783
   PubMed Web of Science ®Google Scholar
• Williams-Noonan, B. J., Yuriev, E., & Chalmers, D. K. (2017). Free energy methods in drug design: Prospects of ‘Alchemical Perturbation’ in medicinal chemistry. Journal of Medicinal Chemistry. doi:10.1021/acs.jmedchem.7b00681
   PubMed Web of Science ®Google Scholar
• Yaacob, N. S., Hamzah, N., Nik Mohamed Kamal, N.N., Zainal Abidin, S.A., Lai, C. S., Navaratnam, V. & Norazmi, M.N. (2010). Anticancer activity of a sub-fraction of dichloromethane extract of Strobilanthes crispus on human breast and prostate cancer cells in vitro. BMC Complementary and Alternative Medicine, 10, 1652.10.1186/1472-6882-10-42
   Web of Science ®Google Scholar
• Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., & Pavletich, N. P. (2013). mTOR kinase structure, mechanism and regulation. Nature, 497(7448), 217–223.10.1038/nature12122
   PubMed Web of Science ®Google Scholar
• Zhou, H., Luo, Y., & Huang, S. (2010). Updates of mTOR Inhibitors. Anti-Cancer Agents in Medicinal Chemistry, 10, 571–581.10.2174/187152010793498663
   PubMed Web of Science ®Google Scholar
• Zhu, J., Wu, J., Frizell, E., Liu, S. L., Bashey, R., Rubin, R., … Zern, M. A. (1999). Rapamycin inhibits hepatic stellate cell proliferation in vitro and limits fibrogenesis in an in vivo model of liver fibrosis. Gastroenterology, 117, 1198–1204.10.1016/S0016-5085(99)70406-3
   PubMed Web of Science ®Google Scholar